Equities

Menicon Co Ltd

Menicon Co Ltd

Actions
Health CareMedical Equipment and Services
  • Price (JPY)1,619.00
  • Today's Change-61.00 / -3.63%
  • Shares traded652.90k
  • 1 Year change-18.58%
  • Beta0.4183
Data delayed at least 20 minutes, as of Nov 15 2024 06:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy1
Outperform3
Hold1
Sell0
Strong Sell0

Share price forecast in JPY

The 4 analysts offering 12 month price targets for Menicon Co Ltd have a median target of 2,250.00, with a high estimate of 2,780.00 and a low estimate of 2,100.00. The median estimate represents a 38.97% increase from the last price of 1,619.00.
High71.7%2,780.00
Med39.0%2,250.00
Low29.7%2,100.00

Dividends in JPY

In 2024, Menicon Co Ltd reported a dividend of 25.00 JPY, equaling last years dividend. The 5 analysts covering the company expect dividends of 27.60 JPY for the upcoming fiscal year, an increase of 10.40%.
Div growth (TTM)0.00%
More ▼

Earnings history & estimates in JPY

On Nov 13, 2024, Menicon Co Ltd reported 2nd quarter 2025 earnings of 24.49 per share.
The next earnings announcement is expected on May 14, 2025.
Average growth rate-11.22%
Menicon Co Ltd reported annual 2024 earnings of 59.65 per share on May 14, 2024.
Average growth rate+6.00%
More ▼

Revenue history & estimates in JPY

Menicon Co., Ltd. had 2nd quarter 2025 revenues of 30.42m. This bettered the 30.30m estimate of the one analyst covering the company. This was 6.93% above the prior year's 2nd quarter results.
Average growth rate+0.65%
Menicon Co., Ltd. had revenues for the full year 2024 of 116.19m. This was 5.44% above the prior year's results.
Average growth rate+8.41%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.